Generated by AI
SPDR S&P Biotech ETF is an exchange-traded fund designed to track an equal-weighted index of U.S. biotechnology stocks. The fund gives investors broad exposure to the biotechnology segment of the healthcare market, with holdings that typically include companies involved in drug discovery, genetic research, therapeutic development, diagnostics, and advanced life sciences tools. Its equal-weighted approach reduces concentration in the largest names and provides more balanced representation across smaller and mid-sized biotech companies. SPDR S&P Biotech ETF is used as a diversified vehicle for gaining exposure to a sector known for innovation, scientific research, and product development across human health and medical technology. Managed by State Street, the fund serves market participants looking for targeted access to the biotech industry through a single pooled portfolio.
The latest articles about XBI.
XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.
RSPH offers broader sector diversification with lower volatility, while XBI delivers higher short-term gains but with steeper drawdowns.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about XBI also mention these. Each card shows that asset’s own numbers for the past 24 hours.